You are leaders in the medical technology sector, operating at the intersection of innovation, regulation, patient outcomes, and commercial performance. With your passion for medtech, many of you are driving operational success today, and some are thinking ahead to expanded governance roles, including serving as a Board Director. The question is: what strategic skills should you be intentionally developing now to prepare for that future?

We live in troubled times. However, even in times of uncertainty, the C-suite searches for strategic opportunities to unlock long-term value. Here are insights that can drive growth in the medtech space.

Communicating a robust economic strategy is paramount to device market success and often requires simplification into a budgetary impact model. Value analysis committees (VAC) hear presentations from medtech companies routinely and yours must stand out clearly.

Communicating a robust economic strategy is paramount to device market success and often requires simplification into a budgetary impact model. Value analysis committees (VAC) hear presentations from medtech companies routinely and yours must stand out clearly.

We all agree that 2023 was an inauspicious year for global medtech M&A. How are other, non Life Sciences (NLS) industries doing in Deal Terms? SRS Aquiom publishes great M&A research in the Life Sciences space for pharma, biotech and medtech. Their value proposition is that SRS Acquiom delivers the smartest way to run a deal™ with solutions that reduce the administrative burden throughout the entire deal lifecycle. Let’s compare global trends of NLS industries to Medtech.

2023 was a discouraging year for worldwide medtech M&A. According to McKinsey, in the life sciences sector, there were 745 transactions in 2023. Ninety-one percent had a value below $1 billion, and 54% fell below $100 million. Biotech and pharma deals were in the majority of deal volume—61% and 23%, respectively.

Expect the pace of medtech innovation in 2024 to meet or exceed the outstanding bump we saw in 2023. And expect price strategies for these new technologies to keep medtech marketing teams on their toes.

Organizational culture is critical for successful innovative growth and the acquisition of new and adjacent technologies. Medtech companies with robust innovation cultures generate even more value by embracing the latest technologies, such as generative AI.

For medtech, resilience over the long term includes expansion through M&A and the bravery to make bold moves to pursue unknown alliances that have a high probability to result in  profitable growth.

According to McKinsey, for a CEO to beat the odds, there are 18 practices divided into six key areas of the job.